Company news

Moderna, Inc. news in 2021

Moderna, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Moderna Announces Supply Agreement with South Korea for Additional 20 Million Doses of Moderna’s COVID-19 Vaccine or Updated Booster Candidate in 2022

December 26, 2021

Moderna Announces Preliminary Booster Data and Updates Strategy to Address Omicron Variant

December 19, 2021

Moderna COVID-19 Vaccine Manufactured in Korea by Samsung Biologics Receives Marketing Authorization from Ministry of Food and Drug Safety of Korea

December 13, 2021

Moderna and Australia Announce Collaboration to Bring mRNA Manufacturing to Australia

December 12, 2021

Moderna Announces Additional 20 Million Doses of COVID-19 Vaccine to COVAX for Supply in 2021 and New Additional Supply Agreement for 2022

December 9, 2021

Moderna Launches AI Academy in Partnership with Carnegie Mellon University

December 8, 2021

Moderna Announces Supply Agreement with the UK for Additional 60 Million Doses of Moderna’s COVID-19 Vaccine in 2022 and 2023

November 30, 2021

Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant

November 25, 2021

Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older

November 18, 2021

Moderna Announces First Participant Dosed in Phase 2/3 Study of its mRNA Respiratory Syncytial Virus (RSV) Vaccine

November 17, 2021

Moderna Files for Authorization of its COVID-19 Vaccine with Health Canada to Include Children Ages 6-11 Years

November 16, 2021

Moderna Announces European Union and European Economic Area Countries to Donate More than 70 Million Doses of Moderna COVID-19 Vaccine to COVAX in 2021 to Help End COVID-19 Pandemic in Low Income Countries

November 15, 2021

Moderna Announces Positive Data from Phase 2 Study of mRNA VEGF-A Therapeutic in Patients Undergoing Coronary Artery Bypass Grafting Surgery

November 14, 2021

Moderna Announces Presentation of Interim Data from Phase 1 Study of mRNA Triplet Program at 2021 SITC Annual Meeting

November 11, 2021

Moderna Files to Expand the Conditional Marketing Authorization for its COVID-19 Vaccine in the European Union to Include Children Ages 6-11 Years

November 8, 2021

Moderna Reports Third Quarter Fiscal Year 2021 Financial Results and Provides Business Updates

November 3, 2021

Moderna and Metagenomi Establish Collaboration to Develop Next-Generation In Vivo Gene Editing Therapeutics

November 1, 2021

Moderna Announces Pledge to Achieve Net-Zero Carbon Emissions Globally by 2030

October 31, 2021

Moderna Provides Update on Timing of U.S. Emergency Use Authorization of its COVID-19 Vaccine for Adolescents

October 30, 2021

Moderna Announces Additional Supply for Q2 2022 of Vaccine for COVAX To Help End COVID-19 Pandemic in Lowest Income Countries

October 28, 2021

Moderna Announces First Participant Dosed in Phase 3 Pivotal Registration Study of Its mRNA Cytomegalovirus (CMV) Vaccine

October 25, 2021

Moderna Announces European Medicines Agency’s Committee for Medicinal Products for Human Use Recommends Booster Dose of Moderna’s COVID-19 Vaccine in the European Union

October 24, 2021

Moderna Announces FDA Authorization of a Booster Dose of Moderna’s COVID-19 Vaccine in the U.S.

October 19, 2021

Moderna Announces FDA Advisory Committee Unanimously Votes in Support of Emergency Use for a Booster Dose of Moderna’s COVID-19 Vaccine in the U.S.

October 13, 2021

Moderna Announces COVAX Exercises Option to Purchase 176.5 Million Additional Doses of Moderna’s COVID-19 Vaccine for Low Income Countries in First Half of 2022

October 11, 2021

Moderna to Build State-of-the-Art mRNA Facility in Africa to Manufacture up to 500 Million Doses Per Year

October 6, 2021

Moderna Announces the Launch of Global Fellowship Program for Young Researchers Exploring mRNA Medicines

October 5, 2021

Moderna Announces European Medicines Agency Authorizes Third Dose of COVID-19 Vaccine for Immunocompromised Individuals Aged 12 Years and Older

October 4, 2021

Moderna to Invest in New Science Center in Cambridge, MA

September 29, 2021

Moderna Announces Supply Agreement with Peru for 20 Million Doses of Its COVID-19 Vaccine

September 23, 2021

Moderna Announces Health Canada Approves its COVID-19 Vaccine

September 15, 2021

Moderna Announces Significant Advances Across Industry-Leading mRNA Portfolio at 2021 R&D Day

September 8, 2021

Moderna and the Institute for Life Changing Medicines Announce a New Collaboration to Develop an mRNA Therapeutic for Ultra-Rare Disease, Crigler-Najjar Syndrome Type 1

September 6, 2021

Moderna Announces Submission of Data to European Medicines Agency for its COVID-19 Vaccine Booster

September 2, 2021

Moderna Announces Submission of Initial Data to U.S. FDA for Its COVID-19 Vaccine Booster

August 31, 2021

Moderna Completes Submission of Biologics License Application to the U.S. Food and Drug Administration for its COVID-19 Vaccine

August 24, 2021

Moderna to Host Virtual R&D Day on Thursday, September 9, 2021

August 23, 2021

Moderna Announces Supply Agreement with Canada for Expanded Supply of Moderna’s COVID-19 Vaccine in 2022, in 2023 and in 2024

August 15, 2021

Moderna Announces FDA Authorization of Third Dose of COVID-19 Vaccine for Immunocompromised Individuals

August 12, 2021

Moderna Announces New Study Showing Its COVID-19 Vaccine Maintains Antibodies Against Variants of Concern and Interest to 6 Months

August 11, 2021

Moderna and Canada Announce Collaboration to Bring mRNA Manufacturing to Canada

August 9, 2021

Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates

August 4, 2021

Moderna Receives FDA Fast Track Designation for Respiratory Syncytial Virus (RSV) Vaccine (mRNA-1345)

August 2, 2021

Moderna Announces First Participant Dosed in Phase 1 Study of Its IL-2 mRNA Therapeutic

August 1, 2021

Moderna Announces Establishment of New Charitable Foundation

July 21, 2021

Moderna Partners with Takeda and the Government of Japan to Supply Additional 50 Million Doses of Moderna’s COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022

July 19, 2021

Moderna to Report Second Quarter Financial Results on Thursday, August 5, 2021

July 14, 2021

Moderna Announces Supply Agreement with Argentina for 20 Million Doses of its COVID-19 Vaccine

July 11, 2021

Moderna Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine

July 6, 2021

Moderna Announces Recipharm Site in France Manufacturing COVID-19 Vaccine Moderna Following Approval by European Medicines Agency

June 30, 2021

Older news releases →

Calls in 2021

Decks in 2021